This VJHemOnc podcast episode explores the evolving role of menin inhibition in the treatment landscape for acute myeloid leukemia (AML), focusing on current challenges and future directions.

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, shares data from the KOMET-007 trial (NCT05735184) evaluating ziftomenib in combination with intensive chemotherapy or azacitidine and venetoclax in AML, and the upcoming Phase III KOMET-017 (NCT07007312) study. Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, and Ghayas Issa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss recognizing and managing differentiation syndrome in menin inhibitor-treated patients. Finally, Dr Zeidner, Emma Searle, MBChB, MA, MRCP, FRCPath, PhD, The Christie NHS Foundation Trust, Manchester, UK, and Justin Watts, MD, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, consider the future of the field, including next-generation menin inhibitors, mechanisms of resistance, combination strategies, and the move of menin inhibition into frontline settings.